

CRISPR-Cas9-Mediated Knock-In Approach to Insert the GFP₁₁ Tag into the Genome of a Human Cell Line

Ryo Tamura and Daichi Kamiyama

Abstract

The protocol in this chapter describes a method to label endogenous proteins using a self-complementing split green fluorescent protein (split GFP_{1-10/11}) in a human cell line. By directly delivering Cas9/sgRNA ribonucleoprotein (RNP) complexes through nucleofection, this protocol allows for the efficient integration of GFP₁₁ into a specific genomic locus via CRISPR-Cas9-mediated homology-directed repair (HDR). We use the GFP₁₁ sequence in the form of a single-stranded DNA (ssDNA) as an HDR template. Because the ssDNA with less than 200 nucleotides used here is commercially synthesized, this approach remains cloning-free. The integration of GFP₁₁ is performed in cells stably expressing GFP₁₋₁₀, thereby inducing fluorescence reconstitution. Subsequently, such a reconstituted signal is analyzed using fluorescence flow cytometry for estimating knock-in efficiencies and enriching the GFP-positive cell population. Finally, the enriched cells can be visualized using fluorescence microscopy.

Key words Split GFP, GFP₁₁, GFP₁₋₁₀, CRISPR, Cas9, Homology-directed repair

1 Introduction

The Human Genome Project has revealed the entire picture of the human genomic landscape and led to the identification of ~25,000 genes that encode cellular proteins [1]. This has laid the groundwork for deciphering how these proteins individually function in a myriad of cellular contexts. Recent molecular and cellular technologies have also assisted researchers in elucidating how proteins cooperate to achieve distinct cellular functions in spatiotemporally regulated manners, providing a more comprehensive view of the proteome. One such technology is fluorescent proteins (FPs), which have transformed cell biology with the ability to visualize proteins of interest using various fluorescence imaging techniques [2]. Previously, an array of FPs has been engineered across and beyond the visible spectrum [3]. These FPs enable simultaneous labeling of multiple proteins in individual live cells, which captures

spatial and temporal dynamics of the proteins and provides mechanistic insights into gene expression regulation, protein modification, and protein-protein interaction [4, 5].

Protein distribution studies have often been carried out through transient transfection in which proteins of interest are tagged with FPs and overexpressed in cells. However, overexpression of FP fusions tends to generate unwanted artifacts (e.g., protein aggregation and mislocalization), making it difficult to interpret the obtained data [6]. Therefore, endogenous gene tagging approaches are preferable [7]. One of the approaches we can use to accomplish endogenous FP tagging is CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9-mediated genome editing. CRISPR-Cas9 system comprises a custom single-guide RNA (sgRNA) and Cas9 protein, which induce a DNA double-strand break to a specific genomic locus in cells. This consequently provides an opportunity to deliberately engineer the locus through homology-directed repair (HDR) [8]. In CRISPR-Cas9-mediated HDR, any altered DNA sequence (including insertions, deletions, and point-mutations) can be flanked by homologous DNA sequences of the corresponding genomic region, resulting in a user-defined, targeted DNA repair [8]. By leveraging CRISPR-Cas9-mediated HDR, we can integrate an FP sequence into a specific protein-coding region, thus visualizing the endogenous localization of target proteins [9].

Because of the relatively large size of FPs (e.g., EGFP is 717 nucleotides [nt] in length), we have to use a long HDR repair template (>1000 nt with homologous DNA sequences), which necessitates multiple steps of molecular cloning to insert the sequence into a backbone plasmid [10]. To simplify CRISPR-Cas9-mediated HDR and provide an efficient approach for protein labeling, we have recently adapted the self-associating split GFP system [10, 11]. In the split GFP system, the beta-barrel scaffold of super-folder GFP is split into two fragments comprising one large fragment and one small fragment, termed GFP₁₋₁₀ and GFP₁₁, respectively. Neither GFP₁₋₁₀ nor GFP₁₁ is fluorescent individually, yet upon co-expression, the two fragments undergo spontaneous assembly and reconstitute fluorescently. The GFP₁₁ fragment has been used as a protein tag. Because the size of the tag is only 48 nt in length [10], this small tag minimizes the length of an HDR repair template (~200 nt in length) and enhances the knock-in efficiency when used for the generation of knock-in cell lines [10]. Moreover, such a short DNA template can be commercially synthesized, making this approach cloning-free. More recently, we and others have developed numerous color variants of split GFP within the visible spectrum, expanding the choice of colors in split FP systems [12–17]. In addition to the visualization of endogenous proteins, these FP₁₁ tags have been employed in a wide range of protein analyses including, but not limited to, quantification of

protein folding [18, 19], determination of protein topology [20, 21], and visualization of protein localization in living cells [22–24]. In this chapter, we describe a protocol to introduce the GFP₁₁ fragment into a specific genomic locus via CRISPR-Cas9-mediated HDR in cultured human cells (see Fig. 1). This protocol is adapted from the method developed by Lin et al. [25] and optimized for genomic integration of GFP₁₁. In conjunction with a cell cycle synchronization technique, the method exploits direct delivery of Cas9/sgRNA ribonucleoprotein (RNP) complexes through nucleofection to maximize the probability of HDR. Furthermore, by co-expressing the complementary GFP₁₋₁₀ fragment, the GFP₁₁-inserted cells can be readily detected by fluorescence flow cytometry and eventually enriched for cellular imaging. Altogether, this protocol provides a simple and efficient way to visualize the localization of endogenous proteins in cultured human cells.

2 Materials

2.1 sgRNA Preparation

1. Pipette tips, RNase-free. 96
2. Microcentrifuge tubes, RNase-free. 97
3. Microcentrifuge. 98
4. Thermocycler. 99
5. Q5 high-fidelity DNA polymerase (New England Biolabs). Other high-fidelity DNA polymerases can be used. 100
6. Zymo DNA Clean & Concentrator-5 (Zymo Research). 102
7. NanoPhotometer N50 (Implen). Other spectrophotometers can be used. 103
8. Diethylpyrocarbonate (DEPC)-treated water (Growcells). 105
9. RNase-free DNA buffer: 2 mM Tris-HCl, pH 8.0, DEPC-treated water. 106
10. MAXIscript Transcription Kit (Invitrogen). Any other commercially available in vitro transcription systems can be used. 108
11. 25 mM NTP mix (New England Biolabs). 110
12. Zymo RNA Clean & Concentrator-5 (Zymo Research). 111
13. RNase-free RNA buffer: 10 mM Tris-HCl, pH 7.0, DEPC-treated water. 112

2.2 Stable Cell Line Creation

1. T-25-cm² flask. 114
2. Tissue culture plate, 24-well. 115
3. Human embryonic kidney 293 cells. 116
4. pcDNA 3.1⁽⁺⁾ mammalian expression vector (Invitrogen). 117
5. 50 mg/mL of Geneticin selective antibiotic (Gibco). 118




Fig. 1 Overview of *GFP₁₁* knock-in generation via CRISPR-Cas9-mediated HDR. Synthetic oligonucleotide primers are used to generate a DNA template. The DNA template enables the production of sgRNA through *in vitro* transcription. A Cas9/sgRNA ribonucleoprotein (RNP) complex is assembled *in vitro*. An ssDNA HDR repair template and the Cas9/sgRNA RNP complex are nucleofected into HEK 293 cells. *GFP₁₁* knock-in cells can be analyzed by flow cytometry to assess the knock-in efficiency and enrich GFP-positive cells or be imaged by fluorescence microscopy to localize the tagged proteins

	6. Dulbecco's modified Eagle medium (DMEM) (HyClone).	119
	7. DMEM medium: DMEM with 10% (v/v) fetal bovine serum (FBS).	120 121
	8. Humidified CO ₂ incubator (37 °C, 5% CO ₂).	122
	9. Opti-MEM (Gibco).	123
	10. 25 kDa linear polyethylenimine (Polysciences, Inc.). Prepare PEI stock solution by diluting linear PEI into a buffer comprising 25 mM HEPES and 150 mM NaCl at pH 7.5. Sterilize the solution via a 0.2-µm filter.	124 125 126 127
	11. Vortexer.	128
2.3 Cell Cycle Synchronization	Nocodazole: To prepare a stock solution, dissolve the nocodazole powder to the final concentration of 100 µg/mL in PBS. The solution should be sterilized through a 0.2-µm filter.	129 130 131
2.4 RNP Complex Assembly	1. Purified Cas9 protein (<i>see Note 1</i>)	132
	2. Tris(2-carboxyethyl)phosphine hydrochloride (TCEP)-HCl	133
	3. Cas9 buffer: 150 mM KCl, 20 mM Tris pH 7.5, 10% v/v glycerol, 1 mM TCEP-HCl, 1 mM MgCl ₂ , DPEC-treated water	134 135 136
	4. Laboratory water bath	137
2.5 Nucleofection	1. Amaxa Cell Line Nucleofector Kit V (Lonza)	138
	2. Nucleofector 2b Device (Lonza)	139
	3. Tissue culture plate, six well	140
2.6 Flow Cytometry	1. Fluorescence-activated cell sorter (FACS) collection tubes, sterile	141 142
	2. CytoFLEX (Beckman Coulter)	143
	3. S3 cell sorter (Bio-Rad)	144
	4. FlowJo software (Treestar, Inc.)	145
2.7 Fluorescence Microscopy	1. 1 mg/mL of fibronectin human plasma (Sigma-Aldrich).	146
	2. Chambered coverglass, eight-well (Lab-Tek).	147
	3. Inverted fluorescence microscope (Nikon) with a Dragonfly spinning disk confocal unit (Andor). Any other confocal microscopes equipped with a 488-nm laser are suitable.	148 149 150
	4. 100 × 1.45 NA oil immersion objective (Nikon).	151
	5. Fiji software (NIH).	152

3 Methods

153

3.1 Pre-experiment Reagent and Cell Preparation

3.1.1 HDR Repair Template Design

Our HDR donor sequence contains a *GFP₁₁* sequence (48 nt in length) and a 3-aa flexible linker (9 nt), flanked by two homology arms (~70 nt); the total length of the donor sequence is ~200 nt. A synthetic ssDNA oligo up to 200 nt can be commercially acquired from custom oligo synthesis services. For tagging with *GFP₁₁*, either N- or C-terminus can be selected depending on its known impact on the localization of a target protein or the availability of neighboring protospacer adjacent motif (PAM) sites in a genomic locus. One example of the HDR template, which is designed to edit the *HIST2H2BE* locus with *GFP₁₁*, is shown in Fig. 2. *HIST2H2BE* encodes histone 2B, which is a core component of nucleosomes. This gene has been successfully targeted with *GFP₁₁* in our previous study [10]. In this case, *GFP₁₁* is inserted into the *HIST2H2BE* locus to tag the encoded protein at the C-terminus with *GFP₁₁*.

3.1.2 sgRNA Preparation

Synthesize target-specific sgRNAs through in vitro transcription using a DNA template (5'- TAATACGACTCACTA TAGGNNNNNNNNNNNNNNNNNNNGTTTAAAGAGC TATGCTGGAAACAGCATAGCAAGTTTAAATAAGGC TAGTCCGTTATCAACTTGAAAAAGTGGCACC GAGTCGGTGCTTTTTTT-3'). The DNA template holds a T7 promoter sequence (TAATAATACGACTCACTATAGG), an ~20-bp gene-specific guide sequence (NNNNNNNNNNNNNNNNNNNN), and a sgRNA scaffold (GTTTAAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC-GAGTCGGTGCTTTTTTT). Prepare the DNA template by an overlapping nested PCR method. This method uses a pair of overlapping forward and reverse primers to generate an initial DNA template and another pair of forward and reverse primers to amplify the template (*see* Fig. 3 for the PCR scheme).

1. To prepare a DNA template, make the following 100 μ L of PCR reaction mix (*see* Table 1 for primer sequences):
 - (a) 2x Q5 polymerase, 50 μ L
 - (b) 12.5 μ M T25 primer, 4 μ L
 - (c) 12.5 μ M BS7 primer, 4 μ L
 - (d) μ M ML611 primer, 0.5 μ L
 - (e) μ M gene-specific primer, 0.5 μ L
 - (f) DEPC-treated water, 41 μ L
2. Run the reaction in a thermocycler using the following PCR condition:




Fig. 2 Example of an HDR repair template design. Top: An HDR template contains a 3-aa linker (black bold upper case), a *GFP₁₁* coding sequence (green bold upper case), and two flanking homology arms for recombination (black lower

- (a) 95 °C for 30 s 196
- (b) 95 °C for 15 s, 57 °C for 15 s, 72 °C for 15 s, 30 cycles 197
- (c) 72 °C for 30 s 198
- (d) °C infinity 199
- 3. Purify the DNA template using Zymo DNA Clean & Concentrator-5 Kit following manufacturer's instructions. Elute DNA with 12 µL RNase-free DNA buffer. 200-202
- 4. Measure the concentration of the eluted DNA using Nano-Photometer N50. The DNA concentration should be ~100 ng/µL. The yield may be different depending on DNA polymerases. 203-206
- 5. To perform in vitro transcription, make the following 100-µL reaction mix: 207-208
 - (a) DNA template, 500 ng 209
 - (b) 25 mM NTP mix, 4 µL 210
 - (c) T7 enzyme mix, 10 µL 211
 - (d) 10x transcription buffer, 10 µL 212
 - (e) DEPC-treated water, up to 100 µL 213
- 6. Incubate the reaction mix at 37 °C for 4 h. 214
- 7. Purify RNA using Zymo RNA Clean & Concentrator-5 Kit following manufacturer's instructions. Elute RNA with 15 µL RNA buffer. 215-217
- 8. Measure the concentration of the eluted RNA using Nano-Photometer N50. The concentration should be ~1000 ng/µL. If the eluted RNA is too concentrated, dilute it with RNA buffer. The eluted sgRNA can be stored at -80 °C until use. 218-222

3.1.3 Stable Cell Line Generation

Prior to generating *GFP₁₁* knock-in cells, one may establish a stable cell line where *GFP₁₋₁₀* is continuously expressed. This allows the cells to achieve the reconstitution of *GFP₁₋₁₀* with *GFP₁₁* after the knock-in event happens. Then, the *GFP₁₁* knock-in cells can be directly brought to various imaging experiments by flow cytometry or fluorescence microscopy. Here, we describe the procedure for establishing HEK 293 cells expressing *GFP₁₋₁₀*. In this method, HEK 293 cells are transfected with a pcDNA3.1 vector containing the *GFP₁₋₁₀* sequence after a CMV promoter (pcDNA3.1-*GFP₁₋₁₀*) and subsequently selected for the stable cell line with Geneticin (this vector contains the Geneticin-resistance gene for selection of

←
Fig. 2 (continued) case). The template is designed to integrate *GFP₁₁* to the 3' end of the *HIST2H2BE* gene immediately upstream of the stop codon (underlined lower case). Bottom: A region within the *HIST2H2BE* locus harboring a ~20 nucleotide sequence for the sgRNA site (purple underlined lower case)

stable lines). Alternatively, other methods, including lentiviral transduction, can be employed to establish a stable cell line (*see Note 2*).

1. Plate HEK 293 cells in DMEM medium to be 80–90% confluent at the time of transfection in a 24-well cell culture plate.
2. Prepare the following (A) and (B) solutions and mix well by pipetting rigorously:
 - (A) 400 ng pcDNA3.1-GFP₁₋₁₀ in 25 μL Opti-MEM
 - (B) 3 μL PEI stock solution in 25 μL Opti-MEM
3. Mix (A) and (B) from the previous step and vortex to form the DNA/PEI complex.
4. Incubate the DNA/PEI cocktail for 5 min at room temperature.
5. Change the culture medium to pre-warmed (37 °C) and fresh DMEM medium.
6. Add the 50 μL DNA/PEI cocktail to the cell culture.
7. Two days after transfection, start feeding DMEM medium containing 500 μg/mL Geneticin every 3–4 days.
8. Continue Geneticin selection until stably transfected HEK 293 cells emerge.

3.1.4 Cell Cycle Synchronization

The CRISPR-Cas9 system introduces double-strand breaks (DSB) through the nuclease activity of Cas9 at a sgRNA-specified genomic locus. Subsequently, the introduced DSBs are repaired by either nonhomologous end-joining (NHEJ) or HDR pathway. Since the HDR pathway is active exclusively in the late S or G2 phase, timed delivery of Cas9/sgRNA RNP complexes with donor HDR templates into synchronized cells could shift the equilibrium toward HDR and thus enhance the knock-in efficiency [26]. Cell cycle synchronization with nocodazole has been shown to increase the efficiency of CRISPR-Cas9-mediated knock-in up to 38% in mammalian cells [25].

1. One day before nucleofection, plate 1.5×10^6 of GFP₁₋₁₀-expressing cells in DMEM medium inside a T-25 flask.
2. Add nocodazole to the cells at the final concentration of 200 ng/mL.

Fig. 3 (continued) overlapping PCR scheme for the synthesis of the DNA template. The DNA template is PCR-amplified using three common primers (T25, ML611, BS7) and a gene-specific primer. See Table 1 for the 5' and 3' primer sequences

Table 1
PCR primers to synthesize a DNA template for sgRNA in vitro transcription

T25 primer	5'-TAA TAC GAC TCA CTA TAG-3'
BS7 primer	5'-AAA AAA AGC ACC GAC TCG GTG C-3'
ML611 primer	5'-AAA AAA AGC ACC GAC TCG GTG CCA CTT TTT CAA GTT GAT AAC GGA CTA GCC TTA TTT AAA CTT GCT ATG CTG TTT CCA GCA TAG CTC TTA AAC-3
Gene-specific primer ^a	5'-TAA TAC GAC TCA CTA TAG GNN NNN NNN NNN NNN NNN NNG TTT AAG AGC TAT GCT GGA A-3'

^aThe gene-specific primer contains an array of “N” dependent on a specific gene sequence a user chooses

3.2 Knock-in Experiment

3.2.1 RNP Complex Assembly

3. Incubate the cells in the CO₂ incubator for ~16 h prior to nucleofection. These cells are ready for nucleofection (*see* Subheading 3.2.2).

Cas9 and sgRNA are conventionally introduced to cells through the Cas9 and sgRNA expression from a plasmid or the direct delivery of a purified Cas9/sgRNA RNP complex. In this method, the latter strategy is used because the direct delivery of the complex into cells leads to genome editing immediately after nucleofection, ensuring the timing of genomic integration within nocodazole-treated cells [25, 27]. In addition, the delivery of such a Cas9/sgRNA RNP complex into cells has furthermore been shown to reduce off-target effects due to a shorter half-life (~12 h) of Cas9 in the RNP complex, compared to that of Cas9 delivered in plasmid [27].

1. Dissolve an HDR template (*see* Subheading 3.1.1) in Cas9 buffer to 100 μM.
2. Thaw purified Cas9 and sgRNA (*see* Subheading 3.1.2) in separate sterile microcentrifuge tubes on ice.
3. Calculate the volumes of sgRNA, Cas9, HDR template, and Cas9 buffer to achieve the following amounts in 50 μL RNP complex cocktail.
 - (a) sgRNA, 650 pmol (*see* Note 3)
 - (b) Cas9, 500 pmol
 - (c) HDR template, 1500 pmol
 - (d) Cas9 buffer, to 50 μL
4. Dilute sgRNA in Cas9 buffer in a sterile microcentrifuge tube.
5. Slowly add Cas9 to diluted sgRNA from the previous step, and gently mix the solution by pipetting up and down.
6. Incubate the RNP complex cocktail at 37 °C for 10 min.

	7. Add the HDR template solution to the RNP complex cocktail, and keep it on ice until nucleofection.	300 301 302
3.2.2 Nucleofection	In this step, the HDR repair template (<i>see</i> Subheading 3.1.1) and Cas9/sgRNA RNP complex (<i>see</i> Subheading 3.2.1) prepared in the previous steps are delivered to the nocodazole-treated HEK 293 cells (<i>see</i> Subheading 3.1.4) through nucleofection. Nucleofection is a form of electroporation developed by Lonza and optimized for the delivery of nucleic acids into a variety of cell lines. Different cell lines require dedicated nucleofection reagents (e.g., Amaxa Cell Line Nucleofector Kit V for HEK 293 cells). To date, various laboratories have successfully employed nucleofection for CRISPR-Cas9 genome editing (<i>see</i> Note 4) [10, 25, 28, 29]. This protocol performs nucleofection via Nucleofector 2b Device (the single cuvette-based system) with its cell-line-specific program.	303 304 305 306 307 308 309 310 311 312 313 314 315
	1. Collect the nocodazole-treated cells. The cells only require gentle pipetting to dissociate for collection. For each nucleofection with Nucleofector 2b Device, 1×10^6 cells are used.	316 317 318
	2. Spin the dissociated cells for 5 min at $3000 \times g$.	319
	3. Resuspend in 1-mL PBS.	320
	4. Remove the supernatant.	321
	5. Subject the harvested cells to nucleofection with Amaxa Cell Line Nucleofector Kit V following manufacturer's instructions. Make sure to use the <i>Q-001</i> program on Nucleofector 2b Device.	322 323 324 325
	6. Add 500 μ L prewarmed DMEM medium to the nucleofected cells, and then transfer to a six-well culture plate.	326 327
	7. Incubate the nucleofected cells in a humidified CO ₂ incubator at 37 °C until analysis. Nucleofected cells typically recover after 2–4 days. Split the nucleofected cells for storage via cryopreservation to prevent the potential dilution of the GFP ₁₁ -inserted cell population by passaging. Use the remainder of the population for the subsequent analyses including flow cytometry and fluorescence microscopy.	328 329 330 331 332 333 334 335
3.3 Post-genome Editing Analysis	To estimate the knock-in efficiency of <i>GFP₁₁</i> , one can load the nucleofected cells to a flow cytometer and measure the number of GFP-positive cells (<i>see</i> Note 5). Once the GFP signal is observed, fluorescence-activated cell sorters (FACS) can enrich the GFP-positive cell population. Such a sorting step eventually facilitates subsequent imaging analyses.	336 337 338 339 340 341
3.3.1 Flow Cytometry	1. Dissociate the nucleofected cells by gently pipetting. Include GFP ₁₋₁₀ -expressing cells as a non-nucleofected control.	342 343
	2. Spin down the dissociated cells for 5 min at $3000 \times g$.	344




Fig. 4 A representative flow cytometry histogram of *GFP₁₁* knock-in HEK 293 cells (green). To estimate the *GFP₁₁* knock-in efficiency of the *HIST2H2BE* locus, *GFP₁₋₁₀*-expressing cells were used as a non-nucleofected control (gray). In this example, ~10% of the nucleofected cells are GFP-positive

3. Resuspend in 0.5 mL PBS and transfer into sterile FACS collection tubes. 345
346
4. Measure the GFP fluorescence signals of the nucleofected and 347
non-nucleofected cells by flow cytometry. GFP is detected 348
using a 488-nm excitation laser and a 535/40-nm band-pass 349
filter. 350
5. Analyze data with FlowJo software. Measure the percentage of 351
the GFP-positive cell population by comparing the nucleo- 352
fected and non-nucleofected cells. As an example of typical 353
results, Fig. 4 shows a representative flow cytometry analysis 354
of *GFP₁₁* knock-in cells, in which endogenous histone 2B 355
proteins are labeled with split GFP. 356
6. The same samples prepared through **steps 1–3** can also be 357
FACS-sorted—sort GFP-positive cells from the population of 358
the nucleofected cells into a sterile FACS collection tube. 359
7. Add 1 mL prewarmed DMEM medium to the sorted cells, and 360
transfer to a 24-well culture plate. 361

	8. Incubate the sorted cells in a humidified CO ₂ incubator at 37 °C until analysis. The sorted cells can be cryopreserved for future use.	362 363 364 365
3.3.2 Fluorescence Microscopy	The functional integration of <i>GFP₁₁</i> into a specific genomic locus and the reconstitution of those split GFP fragments can be validated using fluorescence microscopy.	366 367 368
	1. Dilute fibronectin to 5 µg/mL in PBS. Fibronectin can be used as a substrate for culturing cells.	369 370
	2. Coat eight-well chambered coverglass slides with 5 µg/mL fibronectin at 37 °C for 30 min or longer.	371 372
	3. Remove the residual fibronectin solution from each well by aspiration.	373 374
	4. Seed ~5 × 10 ⁴ of GFP-positive cells (<i>see</i> Subheading 3.3.1) into each well.	375 376
	5. Incubate cells for 4 h or overnight in a humidified CO ₂ incubator at 37 °C.	377 378
	6. Visualize GFP signals on a confocal microscope. GFP is excited by a 488-nm laser and detected by a 525/50-nm band-pass filter. Depending on the endogenous expression levels of target proteins, acquisition parameters (e.g., laser power, exposure time) may vary.	379 380 381 382 383
	7. Analyze the acquired data with Fiji software. See Fig. 5 for a representative confocal image of endogenous histone 2B proteins labeled with split GFP at 100× magnification. The same cells used in Fig. 4 were imaged (<i>see</i> Note 6).	384 385 386 387 388

4 Notes

1. Purified Cas9 proteins are available from commercial vendors (e.g., Invitrogen TrueCut Cas9 protein v2). In addition, recombinant Cas9 proteins can be readily expressed and purified in *E. coli*. For example, bacterially expressed His-tagged Cas9 protein can be affinity-purified via standard Ni-NTA agarose affinity chromatography [30]. A variety of plasmids encoding His-tagged Cas9 can be obtained from Addgene (e.g., pET-28b-Cas9-His, # 47327). 389
390
391
392
393
394
395
396
2. In creating GFP₁₋₁₀-expressing cells, antibiotic selection using Geneticin would be our first choice due to the ease of the selection process. It only requires transfection with one single plasmid encoding the *GFP₁₋₁₀* gene and the Geneticin resistance gene. After antibiotic selection for ~14 days, stable cell lines can be obtained. In contrast, lentiviral transduction requires multiple plasmids for an initial transfection into 397
398
399
400
401
402
403




Fig. 5 A representative confocal image of *GFP₁₁* knock-in HEK 293 cells. Endogenous H2B proteins are labeled with split GFP. The resulting reconstituted GFP signal displays the nuclear localization of histone 2B. Scale bar, 20 μ m

packaging cells to produce viral particles, which should be 404
performed separately prior to the viral transduction into target 405
cells. Moreover, additional safety precautions should be 406
required during the procedure [31]. 407

3. The molecular weight of sgRNA is ~37 kDa (e.g., 1850 ng/ μ L 408
of sgRNA is ~50 μ M). 409

4. Another standard method to directly deliver Cas9/sgRNA 410
complexes into cells is the Neon transfection system from 411
Invitrogen [32–35]. The Neon transfection system has also 412
shown efficient transfection and nuclear uptake in various cell 413
lines [36, 37]. 414

5. Detection of endogenous proteins with split GFP is dependent 415
on their expression levels. In the case of split GFP, ~30% of 416
cellular proteins are estimated to be detected using a single 417
copy of GFP₁₁ [10]. For proteins with low expression levels, 418
inserting tandem repeats of GFP₁₁ can enhance the reconsti- 419
tuted GFP signal from these proteins [10]. 420

6. To characterize the specific genomic integration of GFP₁₁, we 421
can perform Sanger or deep sequencing [25]. To verify the 422
localization of GFP₁₁-tagged proteins, we can perform 423

immunofluorescence using available antibodies against the proteins themselves [10, 11]. 424
425

Acknowledgments 426

We want to thank all members of the Kamiyama lab for critical 427
comments on the manuscript; we particularly thank Melissa Inal 428
and Kathy Bui for helpful discussion. This work was supported by 429
an NIH R01 NS107558 (R.T. and D.K.). Ryo Tamura was sup- 430
ported by the Nakajima Foundation. 431

433 References

- 435 1. Leroy H, Lee R (2013) The Human Genome 475
436 Project: big science transforms biology and 476
437 medicine. *Genome Med* 5:79 477
- 438 2. Shaner NC, Patterson GH, Davidson MW 478
439 (2007) Advances in fluorescent protein tech- 479
440 nology. *J Cell Sci* 120:4247–4260 480
- 441 3. Rizzo MA, Davidson MW, Piston DW (2009) 481
442 Fluorescent protein tracking and detection: 482
443 applications using fluorescent proteins in living 483
444 cells. *Cold Spring Harb Protoc* 2009:pdb.
445 top64 484
- 446 4. Lu W, Lakonishok M, Gelfand VI (2021) Gate- 486
447 keeper function for Short stop at the ring 487
448 canals of the *Drosophila* ovary. *Curr Biol* 31:
449 3207–3220 488
- 450 5. Sengupta P, Seo AY, Pasolli HA, Song YE, 489
451 Johnson MC, Lippincott-Schwartz J (2019) A 490
452 lipid-based partitioning mechanism for selec- 491
453 tive incorporation of proteins into membranes 492
454 of HIV particles. *Nat Cell Biol* 21:452–461 493
- 455 6. Gibson TJ, Seiler M, Veitia RA (2013) The 494
456 transience of transient overexpression. *Nat*
457 *Methods* 10:715–721 495
- 458 7. Doyon JB, Zeitler B, Cheng J, Cheng AT, 496
459 Cherone JM, Santiago Y, Lee AH, Vo TD, 497
460 Doyon Y, Miller JC, Paschon DE, Zhang L, 498
461 Rebar EJ, Gregory PD, Urnov FD, Drubin DG 499
462 (2011) Rapid and efficient clathrin-mediated 500
463 endocytosis revealed in genome-edited mam- 501
464 malian cells. *Nat Cell Biol* 13:331–337 502
- 465 8. Hsu PD, Lander ES, Zhang F (2014) Develop- 503
466 ment and applications of CRISPR-Cas9 for 504
467 genome engineering. *Cell* 157:1262–1278 505
- 468 9. Roberts B, Haupt A, Tucker A, Grancharova T, 506
469 Arakaki J, Fuqua MA, Nelson A, Hookway C, 507
470 Ludmann SA, Mueller IA, Yang R, Horwitz R, 508
471 Rafelski SM, Gunawardane RN (2017) System- 509
472 atic gene tagging using CRISPR/Cas9 in 510
473 human stem cells to illuminate cell organiza- 511
474 tion. *Mol Biol Cell* 28:2854–2874 512
10. Leonetti MD, Sekine S, Kamiyama D, Weiss- 513
man JS, Huang B (2016) A scalable strategy for 514
high-throughput GFP tagging of endogenous 475
human proteins. *Proc Natl Acad Sci U S A* 113:
3501–3508 476
477
478
479
11. Kamiyama D, Sekine S, Barsi-Rhynne B, Hu J, 480
Chen B, Gilbert LA, Ishikawa H, Leonetti 481
MD, Marshall WF, Weissman JS, Huang B 482
(2016) Versatile protein tagging in cells with 483
split fluorescent protein. *Nat Commun* 7:
11046 484
485
12. Feng S, Sekine S, Pessino V, Li H, Leonetti 486
MD, Huang B (2017) Improved split fluores- 487
cent proteins for endogenous protein labeling. 488
Nat Commun 8:370 489
13. Feng S, Varshney A, Coto Villa D, Modavi C, 490
Kohler J, Farah F, Zhou S, Ali N, Muller JD, 491
Van Hoven MK, Huang B (2019) Bright split 492
red fluorescent proteins for the visualization of 493
endogenous proteins and synapses. *Commun*
Biol 2:344 494
495
14. Zhou S, Feng S, Brown D, Huang B (2020) 496
Improved yellow-green split fluorescent pro- 497
teins for protein labeling and signal amplifica- 498
tion. *PLoS One* 15:e0242592 499
15. Tamura R, Jiang F, Xie J, Kamiyama D (2021) 500
Multiplexed labeling of cellular proteins with 501
split fluorescent protein tags. *Commun Biol* 4:
257 502
503
16. Chun W, Waldo GS, Johnson GV (2007) Split 504
GFP complementation assay: a novel approach 505
to quantitatively measure aggregation of tau 506
in situ: effects of GSK3beta activation and cas- 507
pase 3 cleavage. *J Neurochem* 103:2529–2539 508
17. Koker T, Fernandez A, Pinaud F (2018) Char- 509
acterization of split fluorescent protein variants 510
and quantitative analyses of their self-assembly 511
process. *Sci Rep* 8:5344 512
18. Cabantous S, Terwilliger TC, Waldo GS 513
(2005) Protein tagging and detection with 514

- 515 engineered self-assembling fragments of green
516 fluorescent protein. *Nat Biotechnol* 23:
517 102–107
- 518 19. Sitron CS, Brandman O (2019) CAT tails drive
519 degradation of stalled polypeptides on and off
520 the ribosome. *Nat Struct Mol Biol* 26:
521 450–459
- 522 20. Kaser S, Willemin M, Schnarwiler F,
523 Schimanski B, Poveda-Huertes D,
524 Oeljeklaus S, Haenni B, Zuber B,
525 Warscheid B, Meisinger C, Schneider A
526 (2017) Biogenesis of the mitochondrial DNA
527 inheritance machinery in the mitochondrial
528 outer membrane of *Trypanosoma brucei*.
529 *PLoS Pathog* 13:e1006808
- 530 21. Inglis AJ, Page KR, Guna A, Voorhees RM
531 (2020) Differential modes of orphan subunit
532 recognition for the WRB/CAML complex.
533 *Cell Rep* 30:3691–3698
- 534 22. Park E, Lee HY, Woo J, Choi D, Dinesh-
535 Kumar SP (2017) Spatiotemporal monitoring
536 of *Pseudomonas syringae* effectors via type III
537 secretion using split fluorescent protein frag-
538 ments. *Plant Cell* 29:1571–1584
- 539 23. Batan D, Braselmann E, Minson M, Nguyen
540 DMT, Cossart P, Palmer AE (2018) A multi-
541 color split-fluorescent protein approach to
542 visualize listeria protein secretion in infection.
543 *Biophys J* 115:251–262
- 544 24. Li X, Zhu T, Tu H, Pan SQ (2020) *Agrobac-*
545 *terium VirE3* uses its two tandem domains at
546 the C-terminus to retain its companion *VirE2*
547 on the cytoplasmic side of the host plasma
548 membrane. *Front Plant Sci* 11:464
- 549 25. Lin S, Staahl BT, Alla RK, Doudna JA (2014)
550 Enhanced homology-directed human genome
551 engineering by controlled timing of CRISPR/
552 Cas9 delivery. *Elife* 3:e04766
- 553 26. Liu M, Rehman S, Tang X, Gu K, Fan Q,
554 Chen D, Ma W (2018) Methodologies for
555 improving HDR efficiency. *Front Genet* 9:691
- 556 27. Kim S, Kim D, Cho SW, Kim J, Kim JS (2014)
557 Highly efficient RNA-guided genome editing
558 in human cells via delivery of purified Cas9
559 ribonucleoproteins. *Genome Res* 24:
560 1012–1019
- 561 28. Lattanzi A, Meneghini V, Pavani G, Amor F,
562 Ramadier S, Felix T, Antoniani C, Masson C,
563 Alibeu O, Lee C, Porteus MH, Bao G,
564 Amendola M, Mavilio F, Miccio A (2019)
565 Optimization of CRISPR/Cas9 delivery to
566 human hematopoietic stem and progenitor
567 cells for therapeutic genomic rearrangements.
568 *Mol Ther* 27:137–150
- 569 29. Kagoya Y, Guo T, Yeung B, Saso K,
570 Anczurowski M, Wang CH, Murata K,
Sugata K, Saijo H, Matsunaga Y, Ohashi Y, 571
Butler MO, Hirano N (2020) Genetic ablation 572
of HLA Class I, Class II, and the T-cell receptor 573
enables allogeneic T cells to be used for adop- 574
tive T-cell therapy. *Cancer Immunol Res* 8: 575
926–936 576
- 577 30. Jinek M, Chylinski K, Fonfara I, Hauer M,
578 Doudna JA, Charpentier E (2012) A program-
579 mable dual-RNA-guided DNA endonuclease
580 in adaptive bacterial immunity. *Science* 337:
581 816–821
- 582 31. Elegheert J, Behiels E, Bishop B, Scott S,
583 Woolley RE, Griffiths SC, Byrne EFX, Chang
584 VT, Stuart DI, Jones EY, Siebold C, Aricescu
585 AR (2018) Lentiviral transduction of mamma-
586 lian cells for fast, scalable and high-level pro-
587 duction of soluble and membrane proteins.
588 *Nat Protoc* 13:2991–3017
- 589 32. Hung KL, Meitlis I, Hale M, Chen CY,
590 Singh S, Jackson SW, Miao CH, Khan IF,
591 Rawlings DJ, James RG (2018) Engineering
592 protein-secreting plasma cells by homology-
593 directed repair in primary human B cells. *Mol*
594 *Ther* 26:456–467
- 595 33. Gundry MC, Brunetti L, Lin A, Mayle AE,
596 Kitano A, Wagner D, Hsu JI, Hoegenauer
597 KA, Rooney CM, Goodell MA, Nakada D
598 (2016) Highly efficient genome editing of
599 murine and human hematopoietic progenitor
600 cells by CRISPR/Cas9. *Cell Rep* 17:
601 1453–1461
- 602 34. Schumann K, Lin S, Boyer E, Simeonov DR,
603 Subramaniam M, Gate RE, Haliburton GE, Ye
604 CJ, Bluestone JA, Doudna JA, Marson A
605 (2015) Generation of knock-in primary
606 human T cells using Cas9 ribonucleoproteins.
607 *Proc Natl Acad Sci U S A* 112:10437–10442
- 608 35. Wu W, Lu Z, Li F, Wang W, Qian N, Duan J,
609 Zhang Y, Wang F, Chen T (2017) Efficient
610 in vivo gene editing using ribonucleoproteins
611 in skin stem cells of recessive dystrophic epider-
612 molysis bullosa mouse model. *Proc Natl Acad*
613 *Sci U S A* 114:1660–1665
- 614 36. Modarai SR, Man D, Bialk P, Rivera-Torres N,
615 Bloh K, Kmiec EB (2018) Efficient delivery
616 and nuclear uptake is not sufficient to detect
617 gene editing in CD34+ cells directed by a ribo-
618 nucleoprotein complex. *Mol Ther Nucleic*
619 *Acids* 11:116–129
- 620 37. Dwivedi PP, Anderson PJ, Powell BC (2012)
621 Development of an efficient, non-viral trans-
622 fection method for studying gene function and
623 bone growth in human primary cranial suture
624 mesenchymal cells reveals that the cells respond
625 to BMP2 and BMP3. *BMC Biotechnol* 12:45